Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Base Year Market Size (2026) | USD 556.85 Million |
| Market Size (2027) | USD 561.86 Million |
| Market Size (2032) | USD 587.61 Million |
| Growth Rate (2027 - 2032) | 0.90 % |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Mexico Insulin Drugs and Delivery Devices Market Analysis by Mordor Intelligence
The Mexico Insulin Drugs And Delivery Devices Market size was valued at USD 556.85 million in 2026 and is estimated to grow from USD 561.86 million in 2027 to reach USD 587.61 million by 2032, at a CAGR of 0.9% during the forecast period (2027-2032).
Mexico experienced one of the highest COVID-19 mortality burdens among individuals with metabolic disorders, particularly diabetes and obesity. During the pandemic, Mexican health authorities consistently identified diabetes as one of the most common comorbidities among severe COVID-19 cases and deaths. This heightened clinical focus on glycemic control increased the importance of uninterrupted insulin therapy and routine diabetes management, supporting demand for insulin products and delivery devices across the country.
Additionally, the Mexican Social Security Institute (IMSS) expanded the use of remote medical consultations and digital healthcare services during the pandemic to ensure continuity of care for patients with chronic diseases, including diabetes. The increased reliance on home-based disease management encouraged patients to maintain insulin therapy outside traditional healthcare settings, contributing to greater utilization of insulin delivery products.
In Mexico, diabetes, especially Type 2, became a healthcare burden as it is the primary cause of death among women and the secondary cause of death among men. Obesity, sedentarism, bad eating habits, genetics, family background, and age are among the factors that lead to developing diabetes. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Thus, the COVID-19 outbreak increased the insulin market's growth.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Mexico Insulin Drugs and Delivery Devices Market Trends and Insights
Rising diabetes prevalence
In Mexico, the diabetes population is expected to rise by about 3.4% over the forecast period.
According to IDF Diabetes Atlas 2021, the prevalence of diabetes in Mexico reached 16.9%, or one in six adults. An estimated 14 million adults in Mexico are living with diabetes. Additionally, 11 million adults in the country have impaired glucose tolerance, which places them at high risk of developing type 2 diabetes. Diabetes-related health expenditure in Mexico has reached USD 20 billion, putting it in the top ten countries or territories with the highest total health expenditure. About 47.5% of people living with diabetes in the country are undiagnosed.
Lack of health insurance deprives the poor of access to services and puts them at risk of financial hardship. To protect the people against excessive health expenditures, Mexico has implemented mechanisms such as community-based health insurance, national health insurance, and targeted public health insurance. Mexico has multiple health insurance providers. The Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (State Employee's Social Security and Social Services Institute, ISSSTE) provides coverage for government employees, and the Instituto Mexicano del Seguro Social (Mexican Social Security Institute, IMSS) covers for private-sector employees. The Seguro Popular (People's Insurance) was launched to protect the working-age population against steep healthcare costs. Enrolment in the Seguro Popular is independent of health status or pre-existing illness; there is no co-payment by the type of health care received, and family contributions are determined solely by the ability to pay.
Leading manufacturers focus on technological innovations and develop advanced insulin products to gain a substantial market share. There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels.
Therefore, owing to the increasing diabetes prevalence, the studied market is anticipated to grow over the analysis period.
The insulin pumps segment is expected to witness the highest growth rate over the forecast period
An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.
Insulin Pump is expected to grow with a CAGR of about 1.9% in the market during the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration. Insulin pump therapy is a well-established insulin administration method for type 1 diabetes people. Pumps are a validated, time-tested therapeutic option in type 1 diabetes at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.
The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients must check their blood glucose levels regularly, monitor their blood glucose levels, and adjust the insulin dosing accordingly, likely to drive segment growth during the forecast period. The use of continuous subcutaneous insulin infusion and continuous glucose monitoring systems has improved patient care and quality of life and is widely used in the ambulatory setting. Increasingly, this technology is also being used in the hospital setting.
The factors above are anticipated to drive market growth over the analysis period.
Competitive Landscape
The Mexico Insulin Drugs and Delivery Devices Market is moderately consolidated, with few significant and generic players. Mergers and acquisitions between the players recently have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.
Mexico Insulin Drugs and Delivery Devices Industry Leaders
-
Novo Nordisk
-
Sanofi
-
Eli Lilly
-
Medtronic
-
Becton Dickinson
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- October 2022: Becton, Dickinson, and Company and Biocorp announced that they had signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology-a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes.
- March 2022: Oramed announced ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets.
Mexico Insulin Drugs and Delivery Devices Market Report Scope
Insulin is mainly used to treat type 1 diabetes but can be used in people with type 2 diabetes if insulin levels remain low despite the use of other types of medications. There are different ways to inject insulin into a patient's body, using syringes, pens, pumps, and jet injectors, giving them various options for insulin delivery. The Mexico Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins) and Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.
Drug
| Basal or Long-acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | |
| Toujeo (Insulin Glargine) | |
| Tresiba (Insulin Degludec) | |
| Basaglar (Insulin Glargine) | |
| Bolus or Fast-acting Insulins | NovoRapid/Novolog (Insulin aspart) |
| Humalog (Insulin lispro) | |
| Apidra (Insulin glulisine) | |
| FIASP (Insulin aspart) | |
| Admelog (Insulin lispro Sanofi) | |
| Traditional Human Insulins | Novolin/Mixtard/Actrapid/Insulatard |
| Humulin | |
| Insuman | |
| Combination Insulins | NovoMix (Biphasic Insulin aspart) |
| Ryzodeg (Insulin degludec and Insulin aspart) | |
| Xultophy (Insulin degludec and Liraglutide) | |
| Soliqua/Suliqua (Insulin glargine and Lixisenatide) | |
| Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars |
Device
| Insulin Pumps | Insulin Pump Devices |
| Insulin Pump Reservoirs | |
| Insulin Infusion sets | |
| Insulin Pens | Cartridges in reusable pens |
| Disposable insulin pens | |
| Insulin Syringes | |
| Insulin Jet Injectors |
| Drug | Basal or Long-acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Basaglar (Insulin Glargine) | ||
| Bolus or Fast-acting Insulins | NovoRapid/Novolog (Insulin aspart) | |
| Humalog (Insulin lispro) | ||
| Apidra (Insulin glulisine) | ||
| FIASP (Insulin aspart) | ||
| Admelog (Insulin lispro Sanofi) | ||
| Traditional Human Insulins | Novolin/Mixtard/Actrapid/Insulatard | |
| Humulin | ||
| Insuman | ||
| Combination Insulins | NovoMix (Biphasic Insulin aspart) | |
| Ryzodeg (Insulin degludec and Insulin aspart) | ||
| Xultophy (Insulin degludec and Liraglutide) | ||
| Soliqua/Suliqua (Insulin glargine and Lixisenatide) | ||
| Biosimilar Insulins | Insulin Glargine Biosimilars | |
| Human Insulin Biosimilars | ||
| Device | Insulin Pumps | Insulin Pump Devices |
| Insulin Pump Reservoirs | ||
| Insulin Infusion sets | ||
| Insulin Pens | Cartridges in reusable pens | |
| Disposable insulin pens | ||
| Insulin Syringes | ||
| Insulin Jet Injectors | ||
Key Questions Answered in the Report
How big is the Mexico Insulin Drugs And Delivery Devices Market?
The Mexico Insulin Drugs And Delivery Devices Market size is expected to reach USD 556.85 million in 2026 and grow at a CAGR of 0.9% to reach USD 587.61 million by 2032.
What is the Mexico Insulin Drugs And Delivery Devices Market sizein 2027?
In 2027, the Mexico Insulin Drugs And Delivery Devices Market size is expected to reach USD 561.86 million.
Who are the key players in Mexico Insulin Drugs And Delivery Devices Market?
Novo Nordisk, Sanofi, Eli Lilly, Medtronic and Becton Dickinson are the major companies operating in the Mexico Insulin Drugs And Delivery Devices Market.
What years does this Mexico Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2025?
In 2025, the Mexico Insulin Drugs And Delivery Devices Market size was estimated at USD 551.88 million. The report covers the Mexico Insulin Drugs And Delivery Devices Market historical market size for years: 2021, 2022, 2023, 2024, 2025, and 2026. The report also forecasts the Mexico Insulin Drugs And Delivery Devices Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.